Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 15/20 | 0.59 |
| ▸ | MLNR | O43193 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | DRD1 | P21728 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | MC3R | P41968 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.59 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.59 |
| ▸ | GHSR | Q92847 | 1/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 15/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6428760 | 1.00 | ADRB2 (0.59) | ADRB2ADRB1MLNRNR1I2ABCB11 | |
| SCHEMBL928498 | 1.00 | ADRB2 (0.59) | ADRB2ADRB1MLNRNR1I2ABCB11 | |
| SCHEMBL23014462 | 1.00 | ADRB2 (0.59) | ADRB2ADRB1MLNRNR1I2ABCB11 | |
| SCHEMBL15614731 | 0.94 | ADRB2 (0.54) | ADRB2ADRB1MLNRNR1I2ABCB11 | |
| SCHEMBL2563406 | 0.90 | ADRB2 (0.47) | ADRB2ADRB1MLNRNR1I2ABCB11 | |
| SCHEMBL28471346 | 0.88 | ADRB2 (0.49) | ADRB2ADRB1MLNRNR1I2ABCB11 | |
| SCHEMBL2586701 | 0.86 | ADRB2 (0.50) | ADRB2ADRB1MLNRNR1I2ABCB11 | |
| SCHEMBL925085 | 0.86 | ADRB2 (0.50) | ADRB2ADRB1MLNRNR1I2ABCB11 | |
| SCHEMBL15614682 | 0.86 | ADRB2 (0.45) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL5429959 | 0.84 | ADRB3 (0.41) | ADRB2ADRB1MLNRNR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013398-A1 | AN IMPROVED PROCESS FOR PREPARATION OF VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Melody Healthcare Pvt. Ltd. (IN) | 2022-06-22 | — | — | EP | claimed |
| US-8198483-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2012-06-12 | — | — | US | claimed |
| US-20110269970-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | claimed |
| US-7982067-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2011-07-19 | — | — | US | claimed |
| US-20110009631-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2011-01-13 | — | — | US | claimed |
| EP-4452924-B1 | PROCESS TO PREPARE VILANTEROL TRIFENATATE | HOVIONE SCIENTIA LTD (IE) | 2025-12-03 | — | — | EP | disclosed |
| US-20250051261-A1 | Process to Prepare Vilanterol Trifenatate | HOVIONE SCIENTIA LIMITED (IE) | 2025-02-13 | — | — | US | disclosed |
| EP-4452924-A1 | PROCESS TO PREPARE VILANTEROL TRIFENATATE | Hovione Scientia Limited (IE) | 2024-10-30 | — | — | EP | disclosed |
| US-20230286898-A1 | METHOD FOR THE PURIFICATION OF VILANTEROL TRIFENATATE | INKE, S.A. (ES) | 2023-09-14 | — | — | US | disclosed |
| WO-2023118833-A1 | PROCESS TO PREPARE VILANTEROL TRIFENATATE | HOVIONE SCIENTIA LIMITED (IE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023118833-A1 | PROCESS TO PREPARE VILANTEROL TRIFENATATE | HOVIONE SCIENTIA LIMITED (IE) | 2023-06-29 | — | — | WO | disclosed |
| US-11414374-B2 | Crystalline forms of vilanterol trifenatate and processes for their preparation | HOVIONE SCIENTIA LIMITED (IE) | 2022-08-16 | — | — | US | disclosed |
| US-20090068273-A1 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| EP-1425001-B1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-7439393-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2008-10-21 | — | — | US | disclosed |
| US-7361787-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2008-04-22 | — | — | US | disclosed |
| US-20080003290-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2008-01-03 | — | — | US | disclosed |
| US-20050075394-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | US | disclosed |
| EP-1425001-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003024439-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051261-A1 | Process to Prepare Vilanterol Trifenatate | AVPR2, CYP2D6, AVPR1B | ADRB2 145/4885ADRB1 144/4885MLNR 87/4885 |
| US-20080003290-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PHOSPHO1, PNMT, PEBP1 | ADRB2 89/4885ADRB1 125/4885MLNR 1160/4885 |
| US-20110269970-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PNMT, HRH2, CHKB | ADRB2 53/4885ADRB1 101/4885MLNR 261/4885 |
| US-20110009631-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PHOSPHO1, PNMT, PEBP1 | ADRB2 265/4885ADRB1 806/4885MLNR 1268/4885 |
| US-20050075394-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | ADRB2 89/4885ADRB1 192/4885MLNR 988/4885 |
| US-20230286898-A1 | METHOD FOR THE PURIFICATION OF VILANTEROL TRIFENATATE | MAP2K5, MAP2K7, MAP2K1 | ADRB2 1903/4885ADRB1 1740/4885MLNR 816/4885 |
| US-20090068273-A1 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | PNMT, CHRM3, HRH4 | ADRB2 18/4885ADRB1 37/4885MLNR 732/4885 |
| US-11414374-B2 | Crystalline forms of vilanterol trifenatate and processes for their preparation | PRKCD, PRKCQ, CYP24A1 | ADRB2 131/4885ADRB1 334/4885MLNR 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.